SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending with heavy debate around its valuation after earnings, with some traders pointing to a high P/E ratio while others highlight strong growth and government contracts as bullish signals. Community chatter also mentions Michael Burry's reported short position adding to bearish sentiment. Discussions include potential price movements and whether the stock is overhyped or poised for further gains.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards, with community members expressing concerns about increased AI spending and questioning the lack of clear monetization timelines which are causing investors to worry. Many are discussing potential support levels and whether the stock is oversold while also noting a significant increase in short interest. Some traders are sharing their bearish outlook, while others remain bullish, viewing the dip as a buying opportunity.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is trending as part of a broader conversation around privacy coins, with some community members drawing comparisons to ZEC's recent price action.  Enthusiasm is building around DASH's limited supply and potential for significant gains, while others point to its possible use cases and developments.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as community members discuss its potential, citing immediate catalysts like caffeine.ai revenue generation. Bullish community members express excitement with some suggesting accumulation and comparing it to previous runs of Zcash. The broader context involves discussions around its technology and comparisons to other cryptocurrencies.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid after-hours volatility following its Q3 earnings release, with community chatter focused on revenue, subscriber growth, and a potential deal with Novo Nordisk. The stock's high trading volume and short interest are contributing to speculation about a possible short squeeze. Investors are closely monitoring the company's growth prospects and strategic partnerships in the competitive telehealth sector.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending downwards following disappointing data from a confirmatory DMD trial, sparking concerns about the future of its PMO therapies; however, the community is debating whether the market reaction is overblown, given the potential for Elevidys to replace these therapies and the company's strong revenue. Some traders are seeing a buying opportunity amidst the dip, while others express concerns about management and potential regulatory hurdles.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: North America, International Personal Care, and International Family Care and Personal. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The International Family Care and Professional segment consists of two core categories: Family Care and Professional, including facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Kimberly-Clark Corp.

Kimberly-Clark ($KMB) is trending due to a proposed $48.7 billion acquisition of Kenvue ($KVUE), with shareholders receiving cash and stock. The community is debating the deal's merits, potential Tylenol lawsuit risks, and whether KMB overpaid, while some see it as a generational buying opportunity amidst baseless legal/political concerns. CEO interview also generating buzz, along with potential stock price implications.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending amid anticipation for upcoming earnings and speculation around new features, with community members discussing potential price movements and the impact of crypto trends on the stock. Some are pointing to a potential partnership with Opendoor, while others are closely watching for signs of manipulation leading up to the earnings release. Overall, there's a mixed sentiment as the community debates the company's long-term prospects.

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Exact Sciences Corp.

Exact Sciences is trending following a strong earnings report, launch of new cancer tests, and subsequent analyst upgrades. Community members are discussing the company's growth potential, particularly with the new Cologuard Plus test and its potential to grab market share from competitors, and some speculate on the possibility of a buyout. Some investors are also excited by the company's unique position for profitable growth for years to come.

Tidal Trust II - Defiance Daily Target 2x Short PLTR ETF

Defiance Daily Target 2x Short PLTR ETF

PLTZ is trending as traders discuss shorting PLTR, with many citing its high valuation and anticipating a pullback. Community members are actively trading PLTZ to capitalize on potential downside in PLTR, while some debate entry and exit strategies. The discussion includes broader market sentiment and the impact of potential market corrections.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immutep's Head & Neck Cancer Therapy Excels

Immutep Ltd (AU:IMM) has released an update. Immutep Ltd has been selected to present its late-breaking abstract at the ESMO Congress 2024, detaili...

Immutep Ltd (PRRUF) Gets a Buy from Canaccord Genuity

In a report released on August 16, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Immutep Ltd (PRRUF Research Report), with a pr...

Immutep Readies Phase III Lung Cancer Trial

Immutep Ltd (AU:IMM) has released an update. Immutep Ltd has received positive feedback from the FDA for their upcoming Phase III trial, TACTI-004...

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immutep (IMMP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF Research Report) and Immutep (IMMP Re...

Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars

Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck...

Immutep Limited (NASDAQ:IMMP) Short Interest Up 5.6% in March

Immutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 1,140,000 shares, an increase...

Immutep (NASDAQ:IMMP) Stock Crosses Above 50-Day Moving Average of $2.35

Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.35 and traded as high as $2.47. Immutep...

Immutep announces first clinical data from 90mg dosing of efti

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who...

Immutep Limited (NASDAQ:IMMP) Short Interest Up 53.4% in January

Immutep Limited (NASDAQ:IMMP  Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling...

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Immutep Limited - ADR

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.83
Prev Close	$1.89
Open	$1.89
Dividend Yield	0.00%
50-Day Moving Average	$1.83
Beta	0.76
Avg. Volume	194,867.65
PE Ratio	-6.73

52-Week High	$2.71
52-Week Low	$1.32
Market Capitalization	$412.14M
EPS (Annual)	-$0.2733
Price to Book	2.84
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IMMP
Immutep LTD ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMMP News

IMMPImmutep LTD ADR